Clik here to view.
Fresenius v. Baxter: BIO files Amicus Brief in Federal Circuit
The Biotechnology Industry Organization filed an amicus brief at the Federal Circuit in the case of Fresenius v. Baxter: BIO is concerned that the panel decision could have a number of unintended...
View ArticleClik here to view.
Nautilus v. Biosig, Baxter v. Fresenius and Limelight v. Akamai
BIO weighed in on three Supreme Court cases in the last few months whose outcome could change the IP landscape for biotechnology companies. BIO’s amicus brief in Nautilus v. Biosig Instruments argues...
View ArticleClik here to view.
Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?
In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first time provided for biosimilar or interchangeable biological drug products. But it was not...
View ArticleClik here to view.
IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter
The IP Track at BIO 2015 had a number of incredible educational sessions concerning the most relevant topics in the biotech sector. Let’s look back at what top experts in the IP field had to say about...
View ArticleClik here to view.
What We’ll Be Talking about at the BIO Spring IPCC Conference
It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee Conference provides informative and interesting educational sessions on what’s happening...
View ArticleComing Down the Pipeline: Patent Cases to Watch in 2017
The Supreme Court returns from recess on February 17, and alongside the likely confirmation of Neil Gorsuch to the bench, a plethora of IP cases are on their agenda. Let’s take a look at some of the...
View Article
